Together, the levels of immune infiltrate and tumor mutation burden and the presence of expanded and activated T cells in a large proportion of these tumors and in the majority of cases with tertiary lymphoid structures suggest that immune checkpoint inhibitors coupled with concomitant suppression of TGF-β signaling may be a viable option for a subgroup of patients.45 Here, TGFB1 is linked to neoplasm.